Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors
Year: 2010
Type: article
Abstract: The hypothesis that bone marrow-derived, circulating endothelial cells incorporate into tumor blood vessels is unresolved. We have measured the numbers of bone marrow-derived versus resident endothelial cells in spontaneous prostate cancers during different stages of tumor progression and in age-matched normal prostates. Bone marrow-derived endothelial cells were rare in dysplasia and in well differentiated cancers representing between 0 and 0.04% of the total tumor mass. Instead, approximately 99% of all tumor-associated bone marrow-derived cells were CD45(+) hematopoietic cells, including GR-1(+), F4-80(+), and CD11b(+) myeloid cells. Similar to peripheral blood mononuclear cells, these tumor-associated myeloid cells expressed matrix metalloproteinases (MMPs), consistent with their proposed catalytic role during tumor angiogenesis. Furthermore, freshly isolated CD11b(+) cells stimulated tumor endothelial cell cord formation by 10-fold in an in vitro angiogenesis assay. The bone marrow is, therefore, a reservoir for cells that augment tumor angiogenesis, but the tumor endothelium is derived primarily from the local environment.
Source: Blood
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Awards: HEPARIN BINDING ANGIOGENIC GROWTH FACTORS, Regulation of Angiogenesis, Tumor endothelial cell abnormalities, G4222947079, G4453311004, Characterizing tumor endothelial cell abnormalities to develop rational anti-angi, G4646919733, G6244281825, Neuropilin and semaphorin, anti-angiogenesis activities and mechanisms, CHARACTERIZATION OF NEUROPILIN, A NOVEL VEGF RECEPTOR, G9000038317, Targeting the vasculature to enhance anti-tumor immunity
OpenAlex ID: W2040075459
